Regulatory updates, policy explainers, and market literacy for research peptide buyers—RUO only. Fresh posts feed the deals hub.
April 21, 2026
When specialty materials cross borders, paper trails matter. This overview lists common document types and why delays occur.
Read →April 21, 2026
For researchers who also follow company-stage science, this guide shows where peptide programs often appear in public company disclosures.
Read →April 20, 2026
When peptide-related drugs advance in the clinic, teams outside clinical development can still use public readouts to inform literature and mechanism mapping.
Read →April 20, 2026
Chain of identity from receipt to vial is a staple of defensible research. This article covers practical inventory control concepts.
Read →April 19, 2026
GLP and cGMP are often cited in quality discussions. This article gives a non-lawyer, lab-focused explanation for comparing vendor documentation practices.
Read →April 19, 2026
Beyond HPLC %, COAs can list orthogonal identity tests, residual solvent levels, and more. This piece walks through common lines on third-party reports.
Read →April 18, 2026
Materials sold for research, laboratory, or analytical use are labeled outside of drug approval pathways. This article explains how to interpret that framing when evaluating vendor documentation.
Read →April 18, 2026
Pharmacy compounding under sections 503A and 503B is a different regulatory frame than RUO research peptides sold as catalog items. This guide separates the concepts.
Read →March 18, 2026
The FDA cleared icotrokinra as the first oral peptide that blocks the IL-23 receptor. Here is what researchers and readers should know.
Read →March 5, 2026
Peptide rules sit at the intersection of FDA drug authority, compounding oversight, and state policy. Here is a careful, primary-source-oriented overview for researchers.
Read →February 20, 2026
The legal status of peptides varies by type, jurisdiction, and intended use. Here is a clear breakdown of what is and is not permitted.
Read →